This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grebe, S. K. G. Articles by Eberhardt, N. L. Search for Related Content PubMed PubMed Citation Articles by Grebe, S. K. G. Articles by Eberhardt, N. L.

Frequent Loss of Heterozygosity on Chromosomes 3p and 17p without VHL or p53 Mutations Suggests Involvement of Unidentified Tumor Suppressor Genes in Follicular Thyroid Carcinoma¹

Departments of Medicine (S.K.G.G., B.M., I.D.H.), Biochemistry (R.B.J., N.L.E.) and Molecular Biology, Laboratory Medicine and Pathology (J.R.G., R.B.J.), and Surgery (C.S.G.), Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905; the Department of Medicine, University of California-San Diego (P.S.-C.W.), La Jolla, California 92093; the Department of Internal Medicine, School of Medicine de Ribeirao Preto (L.M.Z.M.), 14049 Ribeirao Preto Sp, Brazil; and the Division of Medical Oncology, University of Colorado Cancer Center (H.A.D.), Denver, Colorado 80262

Address all correspondence and requests for reprints to: Norman L. Eberhardt, Ph.D., 4–407 Alfred, Saint Mary’s Hospital, Mayo Clinic, Rochester, Minnesota 55905. E-mail: eberhardt{at}mayo.edu

Follicular thyroid carcinoma (FTC) exhibits frequent loss of heterozygosity (LOH) on chromosomes 10q and 3p, suggesting involvement of tumor suppressor genes. We screened 14 FTC (10 Hurthle cell carcinomas and 4 nonoxyphilic FTC), 14 papillary thyroid carcinomas, and 7 follicular adenomas for LOH on chromosome arms 1p, 3p, 3q, 10p, 10q, 11p, 11q, 13q, 17p, and 17q. LOH was more frequent in FTC than in follicular adenoma or papillary thyroid carcinoma. In FTC, rates of LOH on 3p (86%), 17p (72%), and 10q (57%) were higher than the average rate of LOH (33%; P < 0.05). Most frequently involved were 3p21–25 and 17p13.1–13.3, the sites for the VHL (3p25–26) and p53 (17p13.1) tumor suppressors. We, therefore, characterized these genes by dideoxy fingerprinting and DNA sequencing. Two FTC had mutations in p53, but only 1 of these exhibited LOH at 17p. No VHL gene mutations were found. Thus, neither p53 nor VHL genes play a significant role in the pathogenesis of differentiated thyroid cancer. LOH on 17p, but not on 3p or 10q, was correlated with mortality. Accordingly, 3p and 10q LOH may represent early, and 17p LOH late, events in FTC development. The data suggest the presence of novel tumor suppressor genes on chromosomes 3p and 17p that may be important in the pathogenesis of FTC.

This article has been cited by other articles:

				B. Joseph, M. Ji, D. Liu, P. Hou, and M. Xing Lack of Mutations in the Thyroid Hormone Receptor (TR) {alpha} and Genes but Frequent Hypermethylation of the TR Gene in Differentiated Thyroid Tumors J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4766 - 4770. [Abstract] [Full Text] [PDF]

				M. Sunde, K. C. Y. McGrath, L. Young, J. M. Matthews, E. L. Chua, J. P. Mackay, and A. K. Death TC-1 Is a Novel Tumorigenic and Natively Disordered Protein Associated with Thyroid Cancer Cancer Res., April 15, 2004; 64(8): 2766 - 2773. [Abstract] [Full Text] [PDF]

				M. A. Aldred, M. E. Ginn-Pease, C. D. Morrison, A. P. Popkie, O. Gimm, C. Hoang-Vu, U. Krause, H. Dralle, S. M. Jhiang, C. Plass, et al. Caveolin-1 and Caveolin-2,Together with Three Bone Morphogenetic Protein-related Genes, May Encode Novel Tumor Suppressors Down-Regulated in Sporadic Follicular Thyroid Carcinogenesis Cancer Res., June 1, 2003; 63(11): 2864 - 2871. [Abstract] [Full Text] [PDF]

				M. N. Nikiforova, R. A. Lynch, P. W. Biddinger, E. K. Alexander, G. W. Dorn II, G. Tallini, T. G. Kroll, and Y. E. Nikiforov RAS Point Mutations and PAX8-PPAR{gamma} Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2318 - 2326. [Abstract] [Full Text] [PDF]

				C. A. French, E. K. Alexander, E. S. Cibas, V. Nose, J. Laguette, W. Faquin, J. Garber, F. Moore Jr, J. A. Fletcher, P. R. Larsen, et al. Genetic and Biological Subgroups of Low-Stage Follicular Thyroid Cancer Am. J. Pathol., April 1, 2003; 162(4): 1053 - 1060. [Abstract] [Full Text] [PDF]

				D. Bodmer, W. van den Hurk, J. J. M. van Groningen, M. J. Eleveld, G. J. M. Martens, M. A. J. Weterman, and A. Geurts van Kessel Understanding familial and non-familial renal cell cancer Hum. Mol. Genet., October 1, 2002; 11(20): 2489 - 2498. [Abstract] [Full Text] [PDF]

				K. Farrand, B. Delahunt, X.-l. Wang, B. McIver, I. D. Hay, J. R. Goellner, N. L. Eberhardt, and S. K. G. Grebe High Resolution Loss of Heterozygosity Mapping of 17p13 in Thyroid Cancer: Hurthle Cell Carcinomas Exhibit a Small 411-Kilobase Common Region of Allelic Imbalance, Probably Containing a Novel Tumor Suppressor Gene J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4715 - 4721. [Abstract] [Full Text] [PDF]

				Loss of Heterozygosity of the Long Arm of Chromosome 7 in Follicular and Anaplastic Thyroid Cancer, but Not in Papillary Thyroid Cancer J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3235 - 3240. [Abstract] [Full Text] [PDF]

				F. Lesueur, M. Stark, T. Tocco, H. Ayadi, M. J. Delisle, D. E. Goldgar, M. Schlumberger, G. Romeo, and F. Canzian Genetic Heterogeneity in Familial Nonmedullary Thyroid Carcinoma: Exclusion of Linkage to RET, MNG1, and TCO in 56 Families J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2157 - 2162. [Abstract] [Full Text]

				S. Hemmer, V.-M. Wasenius, S. Knuutila, K. Franssila, and H. Joensuu DNA Copy Number Changes in Thyroid Carcinoma Am. J. Pathol., May 1, 1999; 154(5): 1539 - 1547. [Abstract] [Full Text] [PDF]